Karen L. Reckamp
About
Karen L. Reckamp is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology.
According to data from OpenAlex, Karen L. Reckamp has authored 269 papers receiving a total of 7.5k indexed citations (citations by other indexed papers that have themselves been cited), including 183 papers in Pulmonary and Respiratory Medicine, 180 papers in Oncology and 60 papers in Molecular Biology. Recurrent topics in Karen L. Reckamp's work include Lung Cancer Treatments and Mutations (168 papers), Colorectal Cancer Treatments and Studies (45 papers) and Lung Cancer Research Studies (40 papers). Karen L. Reckamp is often cited by papers focused on Lung Cancer Treatments and Mutations (168 papers), Colorectal Cancer Treatments and Studies (45 papers) and Lung Cancer Research Studies (40 papers). Karen L. Reckamp collaborates with scholars based in United States, South Korea and Canada. Karen L. Reckamp's co-authors include Steven M. Dubinett, Robert A. Figlin, Sherven Sharma, Sumanta K. Pal, Felicita Baratelli, Seok-Chul Yang, Hua Yu, Mariam Dohadwala, Kostyantyn Krysan and Natasha B. Leighl and has published in prestigious journals such as Nucleic Acids Research, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
In The Last Decade
Karen L. Reckamp
255 papers receiving 7.4k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Karen L. Reckamp United States | 41 | 4.1k | 3.4k | 2.4k | 1.5k | 1.4k | 269 | 7.5k | ||
| Alessandro Morabito Italy | 40 | 4.8k 1.2× | 3.4k 1.0× | 1.7k 0.7× | 1.7k 1.1× | 441 0.3× | 217 | 7.2k | ||
| Daniel D. Karp United States | 43 | 4.8k 1.2× | 3.8k 1.1× | 2.9k 1.2× | 1.6k 1.1× | 565 0.4× | 217 | 9.4k | ||
| Alan B. Sandler United States | 44 | 4.5k 1.1× | 3.7k 1.1× | 2.4k 1.0× | 1.0k 0.7× | 638 0.5× | 109 | 7.5k | ||
| William D. Figg United States | 52 | 3.1k 0.8× | 3.8k 1.1× | 4.6k 1.9× | 2.4k 1.6× | 625 0.4× | 234 | 10.3k | ||
| Michael Millward Australia | 48 | 4.4k 1.1× | 1.9k 0.6× | 3.2k 1.4× | 1.3k 0.9× | 1.2k 0.9× | 277 | 7.7k | ||
| Linda T. Vahdat United States | 52 | 7.5k 1.9× | 2.1k 0.6× | 3.6k 1.5× | 2.7k 1.8× | 837 0.6× | 236 | 11.5k | ||
| Gideon M. Blumenthal United States | 47 | 4.0k 1.0× | 2.6k 0.7× | 2.4k 1.0× | 1.3k 0.9× | 926 0.7× | 119 | 7.5k | ||
| Taofeek K. Owonikoko United States | 52 | 5.8k 1.4× | 3.4k 1.0× | 3.8k 1.6× | 1.4k 0.9× | 1.6k 1.1× | 326 | 10.7k | ||
| William L. Dahut United States | 56 | 5.2k 1.3× | 4.3k 1.3× | 3.2k 1.3× | 1.6k 1.1× | 2.8k 2.0× | 291 | 10.4k | ||
| Anish Thomas United States | 43 | 3.7k 0.9× | 2.9k 0.9× | 2.8k 1.2× | 983 0.7× | 926 0.7× | 161 | 8.5k |
Countries citing papers authored by Karen L. Reckamp
Since
Specialization
Citations
This map shows the geographic impact of Karen L. Reckamp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karen L. Reckamp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karen L. Reckamp more than expected).
Fields of papers citing papers by Karen L. Reckamp
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Karen L. Reckamp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karen L. Reckamp. The network helps show where Karen L. Reckamp may publish in the future.
Co-authorship network of co-authors of Karen L. Reckamp
This figure shows the co-authorship network connecting the top 25 collaborators of Karen L. Reckamp. A scholar is included among the top collaborators of Karen L. Reckamp based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karen L. Reckamp. Karen L. Reckamp is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Redman, Mary W., Hatim Husain, Karen L. Reckamp, et al.. (2024). Lung-MAP S1800D: A phase II/III study of N-803 (ALT-803) plus pembrolizumab versus standard of care in participants with stage IV or recurrent non-small cell lung cancer (NSCLC) previously treated with anti-PD-1 or anti-PD-L1 therapy.. Journal of Clinical Oncology. 42(16_suppl). 2619–2619.
2.
Wang, Yingying, Anthony P. Fernandez, Bing Liu, et al.. (2024). EGFR-mediated HSP70 phosphorylation facilitates PCNA association with chromatin and DNA replication. Nucleic Acids Research. 52(21). 13057–13072.
3.
Reckamp, Karen L., Mary W. Redman, Konstantin H. Dragnev, et al.. (2024). SWOG S2302, PRAGMATICA-LUNG: A prospective randomized study of ramucirumab plus pembrolizumab (PR) versus standard of care (SOC) for participants previously treated with immunotherapy for stage IV or recurrent non-small cell lung cancer.. Journal of Clinical Oncology. 42(16_suppl). TPS8657–TPS8657.
4.
Gettinger, Scott, Karen L. Reckamp, Jeffrey A. Moscow, et al.. (2024). Phase II Trial of Afatinib in Patients With EGFR-Mutated Solid Tumors Excluding Lung Cancer: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A. JCO Precision Oncology. 8(8). e2300725–e2300725.
5.
Padda, Sukhmani K., Mary W. Redman, David E. Gerber, et al.. (2023). ECOG-ACRIN LUNG-MAP S1900E substudy: A phase II study of sotorasib in participants (Pts) with previously treated stage IV or recurrent KRAS G12C mutant non-squamous (Non-sq) non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 41(16_suppl). TPS9143–TPS9143.
6.
Kim, Kyung, Edwin M. Posadas, Kevin S. Scher, et al.. (2023). System-wide approach on biosimilars adoption in oncology: Strategic plan on switching and cost savings.. Journal of Clinical Oncology. 41(16_suppl). 1600–1600.
7.
Page, Ray D., Leylah Drusbosky, Victoria M. Raymond, et al.. (2021). Clinical Outcomes for Plasma-Based Comprehensive Genomic Profiling Versus Standard-of-Care Tissue Testing in Advanced Non–Small Cell Lung Cancer. Clinical Lung Cancer. 23(1). 72–81.
8.
Durm, Greg Andrew, Salma K. Jabbour, Sandra K. Althouse, et al.. (2020). A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non–small cell lung cancer: Hoosier Cancer Research Network LUN 14‐179. Cancer. 126(19). 4353–4361.
9.
Huber, Rudolf M., Karin Holmskov Hansen, Luis Paz-Ares Rodríguez, et al.. (2019). Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial. Journal of Thoracic Oncology. 15(3). 404–415.
10.
Rich, Thereasa A., Karen L. Reckamp, Young Kwang Chae, et al.. (2019). Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations. Clinical Cancer Research. 25(19). 5832–5842.
11.
Leighl, Natasha B., Ray D. Page, Victoria M. Raymond, et al.. (2019). Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer. Clinical Cancer Research. 25(15). 4691–4700.
12.
Horn, Leora, Jeffrey R. Infante, Karen L. Reckamp, et al.. (2018). Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study. Clinical Cancer Research. 24(12). 2771–2779.
13.
Gu, Long, Robert Lingeman, Emily Sun, et al.. (2018). The Anticancer Activity of a First-in-class Small-molecule Targeting PCNA. Clinical Cancer Research. 24(23). 6053–6065.
14.
Krysan, Kostyantyn, Rebecca Kusko, Tristan Grogan, et al.. (2014). PGE2-Driven Expression of c-Myc and OncomiR-17-92 Contributes to Apoptosis Resistance in NSCLC. Molecular Cancer Research. 12(5). 765–774.
15.
Frankel, Paul, Timothy W. Synold, Joanne Mortimer, et al.. (2014). Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors. British Journal of Cancer. 111(12). 2268–2274.
16.
Hong, Xin, Andreas Herrmann, Karen L. Reckamp, et al.. (2011). Antiangiogenic and Antimetastatic Activity of JAK Inhibitor AZD1480. Cancer Research. 71(21). 6601–6610.
17.
Lara, Primo N., Jeff Longmate, Karen L. Reckamp, et al.. (2011). Randomized Phase II Trial of Concurrent Versus Sequential Bortezomib Plus Docetaxel in Advanced Non–Small-Cell Lung Cancer: A California Cancer Consortium Trial. Clinical Lung Cancer. 12(1). 33–37.
18.
Kujawski, Maciej, Chunyan Zhang, Andreas Herrmann, et al.. (2010). Targeting STAT3 in Adoptively Transferred T Cells Promotes Their In Vivo Expansion and Antitumor Effects. Cancer Research. 70(23). 9599–9610.
19.
Herrmann, Andreas, Marcin Kortylewski, Maciej Kujawski, et al.. (2010). Targeting Stat3 in the Myeloid Compartment Drastically Improves the In vivo Antitumor Functions of Adoptively Transferred T Cells. Cancer Research. 70(19). 7455–7464.
20.
Planque, Chris, Lin Li, Yingye Zheng, et al.. (2008). A Multiparametric Serum Kallikrein Panel for Diagnosis of Non–Small Cell Lung Carcinoma. Clinical Cancer Research. 14(5). 1355–1362.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Alessandro Morabito Breakdown of academic impact, for papers by Daniel D. Karp Breakdown of academic impact, for papers by Alan B. Sandler Breakdown of academic impact, for papers by William D. Figg Breakdown of academic impact, for papers by Michael Millward Breakdown of academic impact, for papers by Linda T. Vahdat Breakdown of academic impact, for papers by Gideon M. Blumenthal Breakdown of academic impact, for papers by Taofeek K. Owonikoko Breakdown of academic impact, for papers by William L. Dahut Breakdown of academic impact, for papers by Anish Thomas